Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine
BioCentury’s roundup of translational news
Philogen immunocytokine for brain cancer
University of Zurich and Swiss Federal Institute of Technology Zurich (ETHZ) scientists reported data from the first three patients with grade III/IV glioblastoma in a Phase I/II trial of Philogen S.p.A.’s Fibromun (L19-TNF) showing intratumoral necrosis within 24 hours of the second infusion. In a Science Translational Medicine paper, they also demonstrated in mice with brain tumors that a mouse version of Fibromun and another immunocytokine reduced tumor size and mortality survival, boosted numbers of tumor-infiltrating lymphocytes and raised levels of proinflammatory cytokines in the tumor microenvironment.
Nordic radiotherapy reduces rituximab resistance
Nordic Nanovector ASA (OSE:NANO) described in The Journal of Nuclear Medicine the use of betalutin (177Lu-satetraxetan-lilotomab) to reverse rituximab resistance in a xenograft mouse model of non-Hodgkin's lymphoma . The radioimmunotherapy plus rituximab inhibited tumor growth and increased survival compared with either treatment alone. The combination therapy is in Phase I testing to treat lymphoma...
BCIQ Company Profiles